Growing Relationship Between Cardiology and Oncology

BOSTON, Sept. 21, 2011 /PRNewswire/ -- The 15th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) will feature a session  titled "Cancer Chemotherapy and Cardiotoxicity" moderated by Dr. Daniel J. Lenihan, Professor of Medicine at Vanderbilt University. The session will focus on the effect of cancer drugs on the presence of heart failure and how oncologists and cardiologists have developed close collaboration in order to work together to benefit patients.  

Dr. Lenihan will moderate the session that concentrates on the growing relationship between oncologists and cardiologists. Scheduled presentations include discussions of long term cancer care and its relation to cardiology, effects of chemotherapy on cardiotoxicity and the effect of heart failure on therapies for cancer patients.  The session highlights how physicians should treat patients and collaborate with other doctors in different areas.

"It's no longer a physician's myopic perspective when caring for a patient; we're all on the same team – the patient's team," said Dr. Lenihan, Professor of Medicine, Vanderbilt University. "As cardiologists engage more and more with oncologists, and vice-versa, we are not only benefiting our current patients but are also enhancing the future of modern medicine."

The session will describe the impact of chemotherapeutic agents on heart failure and will discuss recommended management options. Doctors will also discuss recent research and discoveries relating to heart failure and its connection to cancer chemotherapy.

For a complete list of annual meeting sessions or for details on attending the conference, call (617) 226-7183 or visit www.hfsa.org and click on Annual Scientific Meeting. There is no registration fee for accredited journalists. Interview areas will be available on-site in addition to a fully-staffed press room with phone and internet accessibility. You may follow news from the meeting on Twitter #HFSA.

About Heart Failure

Heart failure is a progressive condition in which the heart muscle becomes weakened after it is injured, most commonly from heart attack or high blood pressure, and gradually loses its ability to pump enough blood to supply the body's needs. Many people are not aware they have heart failure because the symptoms are often mistaken for signs of getting older. Heart failure affects 4.6 to 4.8 million individuals in the United States. Demographic and clinical evidence strongly suggests that the prevalence of heart failure will increase throughout the next decade. Ten to 15 years ago heart failure was considered a "death sentence;" however, recent advances in treatment have shown that early diagnosis and proper care in early stages of the condition are key to slowing, stopping or in some cases reversing progression, improving quality of life, and extending life expectancy. For more information on heart failure, please visit www.abouthf.org.

About the Heart Failure Society of America

The Heart Failure Society of America (HFSA) is a nonprofit educational organization, founded in 1994 as the first organized association of heart failure experts. The HFSA provides a forum for all those interested in heart function, heart failure research and patient care. The Society also serves as a resource for governmental agencies (FDA, NIH, NHLBI, CMS). The HFSA Annual Scientific Meeting is designed to highlight recent advances in the development of strategies to address the complex epidemiological, clinical and therapeutic issues of heart failure. Additional information on HFSA can be found at www.hfsa.org.

SOURCE The Heart Failure Society of America

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED